Iclusig is a medicine containing the active ingredient(s) ponatinib. On this page you will find out more about Iclusig, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: ponatinib
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Iclusig 15 mg film-coated tablet, 60
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Iclusig is indicated for the treatment of adult patients with:,1. Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia whose disease is resistant to, or who are intolerant of at least two prior tyrosine kinase inhibitors; or where there is a T315I mutation.,2. Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) whose disease is resistant to, or who are intolerant of dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or where there is a T315I mutation.,Therapy with Iclusig should be initiated and monitored by a haematologist with expertise in managing adult leukaemias.
Table of characteristics
|Visual appearance||Tablets are white, biconvex, round film-coated tablets debossed with 'A5' on one side.|
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
Bottles of 30 tablets: Prescription Only Medicine, or Prescription Animal Remedy
Bottles of 60 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||Store in Original Container,Protect from Light|
|Life time||36 Months|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.